| Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ... Journal of thoracic oncology 13 (9), 1248-1268, 2018 | 633 | 2018 |
| Genotyping and genomic profiling of non–small-cell lung cancer: implications for current and future therapies T Li, HJ Kung, PC Mack, DR Gandara Journal of Clinical Oncology 31 (8), 1039-1049, 2013 | 581 | 2013 |
| Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers CM Blakely, TBK Watkins, W Wu, B Gini, JJ Chabon, CE McCoach, ... Nature genetics 49 (12), 1693-1704, 2017 | 490 | 2017 |
| Aurora kinases as anticancer drug targets O Gautschi, J Heighway, PC Mack, PR Purnell, PN Lara Jr, DR Gandara Clinical Cancer Research 14 (6), 1639-1648, 2008 | 475 | 2008 |
| Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ... Journal of Thoracic Oncology 16 (10), 1647-1662, 2021 | 371 | 2021 |
| A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer RK Ramanathan, CP Belani, DA Singh, M Tanaka, HJ Lenz, Y Yen, ... Cancer chemotherapy and pharmacology 64, 777-783, 2009 | 339 | 2009 |
| The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients OA Zill, KC Banks, SR Fairclough, SA Mortimer, JV Vowles, R Mokhtari, ... Clinical Cancer Research 24 (15), 3528-3538, 2018 | 330 | 2018 |
| Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant … A Goldkorn, B Ely, DI Quinn, CM Tangen, LM Fink, T Xu, P Twardowski, ... Journal of clinical oncology 32 (11), 1136-1142, 2014 | 327 | 2014 |
| RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer G Hrustanovic, V Olivas, E Pazarentzos, A Tulpule, S Asthana, ... Nature medicine 21 (9), 1038-1047, 2015 | 292 | 2015 |
| Lung Master Protocol (Lung-MAP)—a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400 RS Herbst, DR Gandara, FR Hirsch, MW Redman, M LeBlanc, PC Mack, ... Clinical cancer research 21 (7), 1514-1524, 2015 | 268 | 2015 |
| Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non–small-cell lung cancer: a model for assessing population-related pharmacogenomics DR Gandara, T Kawaguchi, J Crowley, J Moon, K Furuse, M Kawahara, ... Journal of clinical oncology 27 (21), 3540-3546, 2009 | 241 | 2009 |
| Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with … TB Dorff, B Goldman, JK Pinski, PC Mack, PN Lara Jr, ... Clinical Cancer Research 16 (11), 3028-3034, 2010 | 240 | 2010 |
| Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC JW Riess, DR Gandara, GM Frampton, R Madison, N Peled, JA Bufill, ... Journal of Thoracic Oncology 13 (10), 1560-1568, 2018 | 222 | 2018 |
| The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation–Positive Non–Small cell lung cancer: Status in 2016 DSW Tan, SS Yom, MS Tsao, HI Pass, K Kelly, N Peled, RC Yung, ... Journal of Thoracic Oncology 11 (7), 946-963, 2016 | 217 | 2016 |
| Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non–muscle-invasive bladder cancer on tumor recurrence: SWOG … EM Messing, CM Tangen, SP Lerner, DM Sahasrabudhe, TM Koppie, ... Jama 319 (18), 1880-1888, 2018 | 214 | 2018 |
| Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group CW Ryan, BH Goldman, PN Lara Jr, PC Mack, TM Beer, CM Tangen, ... Journal of clinical oncology 25 (22), 3296-3301, 2007 | 200 | 2007 |
| Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial DI Quinn, CM Tangen, M Hussain, PN Lara, A Goldkorn, CM Moinpour, ... The lancet oncology 14 (9), 893-900, 2013 | 181 | 2013 |
| Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non–small-cell lung cancer AM Davies, C Ho, PN Lara Jr, P Mack, PH Gumerlock, DR Gandara Clinical lung cancer 7 (6), 385-388, 2006 | 159 | 2006 |
| Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317 MS Gordon, M Hussey, RB Nagle, PN Lara Jr, PC Mack, J Dutcher, ... Journal of Clinical Oncology 27 (34), 5788-5793, 2009 | 136 | 2009 |
| Origin and prognostic value of circulating KRAS mutations in lung cancer patients O Gautschi, B Huegli, A Ziegler, M Gugger, J Heighway, D Ratschiller, ... Cancer letters 254 (2), 265-273, 2007 | 128 | 2007 |
Sai-Hong Ignatius OuUniversity of California Irvine在 uci.edu 的电子邮件经过验证
